Jennifer Beck, PA
Physician Assistant · Wexford, PANPI 1114360591
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Amgen accounts for 74.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $5,627 and has fallen 94.1% since, to $334 in 2025. Among physician assistant clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 289 payments — averaging $59.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$13K
- AbbVie$1K
- Novartis$773
- GSK$628
- Johnson & Johnson$627
- AstraZeneca$586
- plus $644 from 11 others
What the payments were for
- Consulting fees$1,2507%
- Speaking & faculty fees$10,25060%
- Travel & lodging$500%
- Food & beverage$5,35431%
- Education$1981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 71 | $12,751 |
| AbbVie | 59 | $1,092 |
| Novartis | 64 | $773 |
| GSK | 23 | $628 |
| Johnson & Johnson | 21 | $627 |
| AstraZeneca(2 entities) | 21 | $586 |
| Pfizer | 5 | $106 |
| E.r. Squibb & Sons, L.L.C. | 5 | $103 |
| Aurinia Pharma U.S., Inc. | 4 | $92 |
| UCB, Inc. | 4 | $92 |
| Boehringer Ingelheim | 3 | $65 |
| Lilly USA, LLC | 3 | $60 |
| Sandoz | 2 | $45 |
| Sobi, Inc | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Fresenius Kabi USA, LLC | 1 | $21 |
| Organon | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,102 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 45 | $416,223 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 32 | $377,742 |
| Humira(Cf) PenAdalimumab | 32 | $332,779 |
| Orencia ClickjectAbatacept | 56 | $327,193 |
| OtezlaApremilast | 49 | $252,568 |
| BenlystaBelimumab | 39 | $198,250 |
| EnbrelEtanercept | 22 | $155,161 |
| SimponiGolimumab | 18 | $142,268 |
| RinvoqUpadacitinib | 13 | $129,652 |
| Xeljanz XrTofacitinib Citrate | 17 | $94,529 |
| Hydroxychloroquine Sulfate | 370 | $18,477 |
| MethotrexateMethotrexate Sodium | 323 | $12,764 |
| Mycophenolate Mofetil | 40 | $6,763 |
| Leflunomide | 65 | $6,189 |
| Sulfasalazine DrSulfasalazine | 73 | $4,997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Enbrel | $12,751 | $407,72871 claims |
| GSKBenlysta | $628 | $198,25039 claims |
| Johnson & JohnsonSimponi | $627 | $142,26818 claims |
| AbbVieRinvoq | $1,092 | $129,65213 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $21 | $3412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Wexford
- Jason OberdickWexford$206K
- Caitlyn StoweWexford$17K
- Melissa HutzlerWexford$17K
- Erin CrownState College$1.2M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Justine RobertsMurrysville$173K
- Allison BoydErie$163K
- Joshua TrbovichWashington$144K
- Daniel TelegaErie$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.